A total of 637 patients with refractory or sensitive SCLC were randomly assigned at a ratio of 2:1 to 21-day cycles of amrubicin 40 mg/m ( 2 ) intravenously ( IV ) on days 1 to 3 or topotecan 1.5 mg/m ( 2 ) IV on days 1 to 5 .